Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells

Authors: Xing-dong Xu, Lan Yang, Li-yun Zheng, Yan-yan Pan, Zhi-fei Cao, Zhi-qing Zhang, Quan-sheng Zhou, Bo Yang, Cong Cao

Published in: BMC Cancer | Issue 1/2016

Login to get access

Excerpt

Unfortunately, the original version of this article [1] contained an error within Fig. 5. For testing Sema4D protein expression in PaTu8988 cells with/out SAHA treatment, the protein samples of Fig. 2D were re-tested by Western blot assay using Sema4D antibody (Fig. 5E). The correct version of Fig. 5E can be found below. This does not alter the conclusion of the result.
Literature
1.
go back to reference Xu X, Yang L, Zheng L, Pan Y, Cao Z, Zhang Z, Zhou Q, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. BMC Cancer. 2014;14:373. doi:10.1186/1471-2407-14-373.CrossRefPubMedPubMedCentral Xu X, Yang L, Zheng L, Pan Y, Cao Z, Zhang Z, Zhou Q, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells. BMC Cancer. 2014;14:373. doi:10.​1186/​1471-2407-14-373.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells
Authors
Xing-dong Xu
Lan Yang
Li-yun Zheng
Yan-yan Pan
Zhi-fei Cao
Zhi-qing Zhang
Quan-sheng Zhou
Bo Yang
Cong Cao
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2401-3

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine